Oruka Therapeutics, Inc. Current Assets
Oruka Therapeutics, Inc. (ORKA) had Current Assets of $884.56 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-10
- 2026-06-30: Assets, Current $884.56M.
- 2026-03-31: Assets, Current $395.25M.
- 2025-12-31: Assets, Current $343.86M.
- 2025-09-30: Assets, Current $355.16M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $884.56M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $395.25M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $343.86M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $355.16M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $332.01M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $352.08M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $376.87M 10-K · filed 2026-03-12 |
| 2024-09-30 | $412.95M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $33.82M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $36.67M 10-Q · filed 2024-04-25 |
| 2024-02-06 | $1.00K 10-K · filed 2025-03-06 |
| 2023-12-31 | $37.59M 10-Q · filed 2024-08-01 |
| 2023-09-30 | $38.89M 10-Q · filed 2023-10-18 |
| 2023-06-30 | $40.76M 10-Q · filed 2023-07-21 |
| 2023-03-31 | $41.70M 10-Q · filed 2023-04-24 |
| 2022-12-31 | $42.70M 10-K · filed 2024-02-01 |
| 2022-09-30 | $44.55M 10-Q · filed 2022-10-28 |
| 2022-06-30 | $47.66M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $50.54M 10-Q · filed 2022-05-02 |
| 2021-12-31 | $54.42M 10-K · filed 2023-02-24 |
| 2021-09-30 | $59.67M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $64.79M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $68.73M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $49.97M 10-K · filed 2022-03-14 |
| 2020-09-30 | $51.94M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $11.57M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $7.38M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $8.48M 10-K · filed 2021-03-18 |
| 2019-09-30 | $9.90M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $10.32M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $8.52M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $6.78M 10-K · filed 2020-02-18 |
| 2018-09-30 | $8.39M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $10.01M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $12.73M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $12.30M 10-K · filed 2019-02-27 |
| 2017-09-30 | $16.38M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $16.66M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $19.85M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $21.45M 10-K · filed 2018-03-22 |
| 2016-09-30 | $23.79M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $26.73M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $31.02M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $38.92M 10-K · filed 2017-03-21 |
| 2015-09-30 | $41.69M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $44.33M 10-Q · filed 2015-08-11 |
| 2015-03-31 | $12.67M 10-Q · filed 2015-05-12 |
| 2014-12-31 | $15.49M 10-K · filed 2016-03-17 |
| 2014-09-30 | $17.46M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $19.68M 10-Q · filed 2014-08-13 |
| 2014-03-31 | $21.80M 10-Q · filed 2014-05-13 |
| 2013-12-31 | $16.93M 10-K · filed 2015-03-19 |
| 2013-09-30 | $19.01M 10-Q · filed 2013-11-13 |
| 2013-06-30 | $20.66M 10-Q · filed 2013-08-13 |
| 2013-03-31 | $3.99M 10-Q · filed 2013-05-13 |
| 2012-12-31 | $3.04M 10-K · filed 2014-03-20 |
| 2012-09-30 | $3.27M 10-Q · filed 2012-11-13 |
| 2012-06-30 | $3.59M 10-Q · filed 2012-08-13 |
| 2012-03-31 | $4.70M 10-Q · filed 2012-05-14 |
| 2011-12-31 | $6.21M 10-K · filed 2013-03-21 |
| 2011-09-30 | $6.09M 10-Q · filed 2011-11-14 |
| 2011-06-30 | $7.83M 10-Q · filed 2011-08-15 |
| 2010-12-31 | $7.16M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |